不可切除III期非小细胞肺癌放化疗前后阿替利珠单抗治疗:II期非随机对照试验
这项单队列II期非随机对照试验在美国11个中心纳入62例不可切除III期非小细胞肺癌患者,在放化疗前给予4周期阿替利珠单抗,放化疗后继续阿替利珠单抗至1年。12周疾病控制率为74.2%(80%CI 65.7%-81.4%),中位无进展生存期30.0个月(95%CI 15.8至不可评估),中位总生存期未达到,24个月总生存率73.7%。17例(27.4%)发生≥3级免疫相关不良事件,包括1例5级肺炎和1例4级吉兰-巴雷综合征。
要点
- 62例不可切除III期NSCLC患者接受放化疗前后阿替利珠单抗治疗,12周疾病控制率74.2%(80%CI 65.7%-81.4%)。
- 中位无进展生存期30.0个月(95%CI 15.8至不可评估),中位总生存期未达到,24个月总生存率73.7%(95%CI 63.4%-85.7%)。
- 17例(27.4%)发生≥3级免疫相关不良事件,包括1例5级肺炎和1例4级吉兰-巴雷综合征;30例(48.4%)发生≥3级治疗相关不良事件。
核心结论
- 这些发现提示,基于安全性和令人鼓舞的结局,新辅助阿替利珠单抗值得进一步研究。
研究设计与样本
- 单队列、II期、非随机对照试验,在美国11个中心开展。
- 纳入病理确诊、不可切除III期NSCLC、未接受过治疗且体能状态良好的患者,2018年1月3日至2019年7月24日入组,数据锁定于2023年3月21日。
- 共62例患者(中位年龄63.9岁,范围38.1-86.5岁;女性32例,占51.6%)接受至少1剂阿替利珠单抗。
主要发现
- 12周疾病控制率为74.2%(80%CI 65.7%-81.4%)。
- 中位无进展生存期为30.0个月(95%CI 15.8至不可评估),中位总生存期未达到。
- 24个月总生存率为73.7%(95%CI 63.4%-85.7%),总缓解率为66.2%。
- 17例(27.4%)发生≥3级免疫相关不良事件,包括1例5级肺炎和1例4级吉兰-巴雷综合征。
- 30例(48.4%)发生≥3级治疗相关不良事件。
关键数值与推荐
- 患者接受4个21天周期阿替利珠单抗1200 mg静脉给药,每周期第1天给药。
- 未进展者继续放化疗(累及野60 Gy)同步每周卡铂曲线下面积2和紫杉醇50 mg/m2,随后计划巩固卡铂曲线下面积6和紫杉醇200 mg/m2,共2个21天周期。
- 未进展者继续阿替利珠单抗1200 mg每21天一次,至完成1年治疗。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Outcomes for patients with unresectable stage III non-small cell lung cancer (NSCLC) treated with chemoradiation therapy (CRT) have improved with adjuvant immune checkpoint inhibitors, with a reported 5-year overall survival benefit of approximately 10% for adjuvant durvalumab vs placebo after completion of CRT without progression and with preserved performance status. Starting atezolizumab prior to CRT may allow more patients to benefit from immunotherapy. OBJECTIVE: To evaluate clinical outcomes of patients treated with atezolizumab before and after CRT for unresectable stage III NSCLC. DESIGN, SETTING, AND PARTICIPANTS: This single-cohort, phase II, nonrandomized controlled trial was conducted at 11 US sites. Patients with pathologically confirmed, unresectable stage III NSCLC who were treatment naive and had good performance status were enrolled between January 3, 2018, and July 24, 2019. Data were locked on March 21, 2023. INTERVENTIONS: Patients received four 21-day cycles of atezolizumab, 1200 mg intravenously, with therapy administered on day 1 of each cycle. Patients not experiencing tumor progression continued to CRT (60 Gy to involved fields) concurrent with weekly carboplatin area under the curve of 2 and paclitaxel, 50 mg/m2, followed by planned consolidation carboplatin area under the curve of 6 and paclitaxel, 200 mg/m2, for two 21-day cycles. Patients not experiencing progression continued atezolizumab, 1200 mg, every 21 days to complete 1 year of therapy. MAIN OUTCOMES AND MEASURES: The primary end point was the disease control rate at 12 weeks. Secondary end points were progression-free survival, overall survival, overall response rate, safety, and translational science end points. RESULTS: A total of 62 patients (median [range] age, 63.9 [38.1-86.5] years; 32 female [51.6%]) were enrolled and received at least 1 dose of atezolizumab. The disease control rate at 12 weeks was 74.2% (80% CI, 65.7%-81.4%). Median progression-free survival was 30.0 months (95% CI, 15.8 to not evaluable), and the median overall survival was not reached. The overall survival rate at 24 months was 73.7% (95% CI, 63.4%-85.7%), and the overall response rate was 66.2%. Seventeen patients (27.4%) experienced grade 3 or higher immune-related adverse events, including 1 with grade 5 pneumonitis and 1 with grade 4 Guillain-Barré syndrome. Thirty patients (48.4%) experienced grade 3 or higher treatment-related adverse events. CONCLUSIONS AND RELEVANCE: These findings suggest that neoadjuvant atezolizumab merits further study based on safety and encouraging outcomes. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03102242.
引用
- Ross HJ, Kozono D, Wang XF, et al. Atezolizumab Before and After Chemoradiation for Unresectable Stage III Non-Small Cell Lung Cancer: A Phase II Nonrandomized Controlled Trial. JAMA Oncol. 2024. PMID: 39052256. doi:10.1001/jamaoncol.2024.1897
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。